Acebis

Leaflet attached to the packaging: Patient information

ACEBIS, 2.5 mg + 1.25 mg, hard capsules
ACEBIS, 2.5 mg + 2.5 mg, hard capsules
ACEBIS, 5 mg + 2.5 mg, hard capsules

ACEBIS, 5 mg + 5 mg, hard capsules

ACEBIS, 10 mg + 5 mg, hard capsules

ACEBIS, 10 mg + 10 mg, hard capsules

ramipril + bisoprolol fumarate

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• In case of any doubts, you should consult a doctor, pharmacist, or nurse.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same as yours.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What ACEBIS is and what it is used for
• 2. Important information before taking ACEBIS
• 3. How to take ACEBIS
• 4. Possible side effects
• 5. How to store ACEBIS
• 6. Contents of the packaging and other information

1. What ACEBIS is and what it is used for

ACEBIS contains two active substances - bisoprolol fumarate and ramipril - in one capsule.

• Ramipril is an angiotensin-converting enzyme (ACE) inhibitor. It works by widening the blood vessels, making it easier for the heart to pump blood to the body.
• Bisoprolol fumarate belongs to a group of medicines called beta-blockers (beta-adrenergic blockers). Beta-adrenergic blockers slow the heart rate and increase the efficiency of the heart in pumping blood to the body.

ACEBIS is used to treat high blood pressure (hypertension) and/or chronic heart failure with left ventricular dysfunction (a condition in which the heart is not able to pump enough blood to meet the body's needs, resulting in shortness of breath and swelling) and/or to reduce the risk of heart events, such as heart attack, in patients with chronic coronary artery disease (a condition in which blood flow to the heart is reduced or blocked) who have already had a heart attack and/or have undergone a procedure to improve blood flow to the heart by widening the blood vessels that supply it, or have diabetes with at least one other cardiovascular risk factor.

2. Important information before taking ACEBIS

When not to take ACEBIS:

• if the patient is allergic to bisoprolol or any other beta-adrenergic blocker, ramipril or any other ACE inhibitor, or any of the other ingredients of this medicine (listed in section 6),
• if the patient has severe heart failure that has suddenly worsened and may require hospital treatment,
• if the patient has cardiogenic shock (a serious heart condition caused by very low blood pressure),
• if the patient has a heart condition characterized by a slow or irregular heart rate (second- or third-degree atrioventricular block, sinoatrial block, sick sinus syndrome),
• if the patient has a slow heart rate,
• if the patient has very low blood pressure,
• if the patient has severe asthma or severe chronic obstructive pulmonary disease (COPD),
• if the patient has serious blood circulation problems in the limbs (such as Raynaud's syndrome) that may cause tingling, pallor, or cyanosis of the fingers and toes,
• if the patient has an untreated pheochromocytoma (a rare tumor of the adrenal gland),
• if the patient has metabolic acidosis, a condition in which the blood contains too much acid,
• if the patient has had symptoms such as wheezing, swelling of the face, lips, tongue, or throat, intense itching, or severe skin rashes during previous treatment with an ACE inhibitor, or if the patient or a family member has had such symptoms in any other circumstances (a condition known as angioedema),
• if the patient is pregnant more than three months (it is also not recommended to take ACEBIS during early pregnancy - see "Pregnancy"),
• if the patient has diabetes or kidney problems and is being treated with a blood pressure-lowering medicine containing aliskiren,
• if the patient is undergoing dialysis or other blood filtration procedures. Depending on the equipment used, ACEBIS may not be suitable for the patient.
• if the patient has kidney problems in which blood flow to the kidneys is reduced (renal artery stenosis),
• if the patient is being treated with sacubitril/valsartan, a combination medicine containing sacubitril and valsartan, used to treat chronic heart failure (see "Warnings and precautions" and "Other medicines and ACEBIS")

Warnings and precautions

Before starting to take ACEBIS, the patient should discuss it with their doctor or pharmacist if:

• the patient has diabetes,
• the patient has kidney problems (including a transplanted kidney) or is undergoing dialysis,
• the patient has liver problems,
• the patient has a narrowing of the aorta and mitral valve (narrowing of the main blood vessel leaving the heart) or hypertrophic cardiomyopathy (a heart muscle disease) or renal artery stenosis (narrowing of the artery supplying the kidney with blood),
• the patient has abnormally high levels of a hormone called aldosterone in the blood (primary aldosteronism),
• the patient has heart failure or any other heart problems, such as minor arrhythmias or severe chest pain at rest (Prinzmetal's angina),
• the patient has a connective tissue disease (such as systemic lupus erythematosus or scleroderma),
• the patient is on a low-salt diet or is taking salt substitutes containing potassium (too much potassium in the blood can cause changes in heart rate),
• the patient has recently had diarrhea or vomiting or is dehydrated (ACEBIS may cause a drop in blood pressure),
• the patient is going to have LDL apheresis (a procedure to remove cholesterol from the blood using a special device),
• the patient is currently undergoing desensitization treatment or is planning to undergo desensitization treatment to reduce the effects of an allergy to bee or wasp stings,
• the patient is on a strict diet or fasting,
• the patient is going to have anesthesia and/or major surgery,
• the patient has circulation problems in the limbs,
• the patient has asthma or COPD,
• the patient has (or has had) psoriasis,
• the patient has an adrenal gland tumor (pheochromocytoma),
• the patient has thyroid disorders (ACEBIS may mask the symptoms of hyperthyroidism),
• the patient has angioedema (a severe allergic reaction with swelling of the face, lips, tongue, or throat with difficulty swallowing or breathing). This can occur at any time during treatment. If such symptoms occur, the patient should stop taking ACEBIS and contact their doctor immediately.
• the patient is black, as they may be at higher risk of angioedema, and ACEBIS may be less effective in lowering blood pressure than in non-black patients,
• the patient is taking any of the following medicines used to treat high blood pressure:
• angiotensin II receptor antagonists (ARBs) (also known as sartans - e.g., valsartan, telmisartan, irbesartan), particularly in patients with diabetic kidney disease.
• aliskiren. The doctor may check kidney function, blood pressure, and electrolyte levels (e.g., potassium) in the blood at regular intervals. See also the information under "When not to take ACEBIS".
• the patient is taking any of the following medicines - the risk of angioedema is increased:
• racecadotril (used to treat diarrhea),
• sirolimus, everolimus, temsirolimus, and other medicines belonging to the class of mTOR inhibitors (used to prevent the rejection of transplanted organs),
• sacubitril (available in a fixed-dose combination with valsartan), used to treat chronic heart failure.

The patient should not stop taking ACEBIS suddenly, as this may cause serious worsening of the heart condition. The patient should not stop treatment suddenly, especially if they have coronary artery disease.
The patient should tell their doctor if they think they may be pregnant (or may become pregnant). ACEBIS is not recommended during early pregnancy and should not be taken after the third month of pregnancy, as it may seriously harm the baby (see "Pregnancy").

Children and adolescents

ACEBIS is not recommended for use in children and adolescents under 18 years of age.

Other medicines and ACEBIS

The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
There are medicines that may change the effect of ACEBIS or whose effect may be changed by ACEBIS. This type of interaction may reduce the effectiveness of one or both medicines. It may also increase the risk or severity of side effects.
The patient should remember to inform their doctor if they are taking any of the following medicines:

• medicines used to control blood pressure or heart diseases (such as amiodarone, amlodipine, clonidine, digitalis glycosides, diltiazem, disopyramide, felodipine, flecainide, lidocaine, methyldopa, moxonidine, procainamide, propafenone, quinidine, rilmenidine, verapamil),

ACEBIS should be taken before a meal.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine.
Pregnancy
The patient should tell their doctor if they think they may be pregnant (or may become pregnant).
The doctor will usually advise the patient to stop taking ACEBIS before becoming pregnant or as soon as pregnancy is confirmed and will prescribe another medicine instead of ACEBIS. ACEBIS is not recommended during early pregnancy and should not be taken after the third month of pregnancy, as it may seriously harm the baby.
Breastfeeding
The patient should inform their doctor about breastfeeding or intending to breastfeed. ACEBIS is not recommended for breastfeeding mothers, and the doctor may choose another treatment for the patient if they want to breastfeed, especially if the baby is a newborn or premature.

Driving and using machines

ACEBIS usually does not affect alertness, but some patients may experience dizziness or weakness due to low blood pressure, especially at the beginning of treatment or after changing the medicine, as well as in combination with alcohol. If these changes occur, the ability to drive or operate machines may be impaired.
Lactose
ACEBIS 2.5 mg + 1.25 mg contains 40.97 mg of lactose (20.49 mg of glucose and 20.49 mg of galactose) per dose. This should be taken into account in patients with diabetes.
ACEBIS 2.5 mg + 2.5 mg contains 40.97 mg of lactose (20.49 mg of glucose and 20.49 mg of galactose) per dose. This should be taken into account in patients with diabetes.
ACEBIS 5 mg + 2.5 mg contains 81.94 mg of lactose (40.97 mg of glucose and 40.97 mg of galactose) per dose. This should be taken into account in patients with diabetes.
ACEBIS 5 mg + 5 mg contains 81.94 mg of lactose (40.97 mg of glucose and 40.97 mg of galactose) per dose. This should be taken into account in patients with diabetes.
ACEBIS 10 mg + 5 mg contains 163.88 mg of lactose (81.94 mg of glucose and 81.94 mg of galactose) per dose. This should be taken into account in patients with diabetes.
ACEBIS 10 mg + 10 mg contains 163.88 mg of lactose (81.94 mg of glucose and 81.94 mg of galactose) per dose. This should be taken into account in patients with diabetes.
Sodium
ACEBIS contains less than 1 mmol of sodium (23 mg) per capsule, which means the medicine is considered "sodium-free".

3. How to take ACEBIS

This medicine should always be taken exactly as prescribed by the doctor or pharmacist. If the patient has any doubts, they should consult their doctor or pharmacist.
The recommended dose is one capsule once a day. The capsule should be swallowed in the morning before a meal, with a glass of water.
Patient with kidney disease
The doctor will adjust the dose of ACEBIS in patients with moderate kidney disease. ACEBIS is not recommended in patients with severe kidney disease.
Patient with liver disease
The doctor will closely monitor patients with mild or moderate liver disease when starting treatment with ACEBIS.

Use in children and adolescents

ACEBIS is not recommended for use in children and adolescents.

Taking a higher dose of ACEBIS than recommended

In case of taking more capsules than prescribed, the patient should immediately contact their doctor or pharmacist.
The most likely effect of an overdose is low blood pressure, which may cause dizziness or fainting (in such cases, lying down with elevated legs may help), severe breathing difficulties, trembling (due to low blood sugar), and slow heart rate.

Missing a dose of ACEBIS

It is important to take the medicine every day, as regular treatment is more effective. However, if a dose of ACEBIS is missed, the next dose should be taken at the usual time. The patient should not take a double dose to make up for the missed dose.

Stopping treatment with ACEBIS

The patient should not stop taking ACEBIS suddenly or change the dose without consulting their doctor, as this may cause serious worsening of the heart condition. The patient should not stop treatment suddenly, especially if they have coronary artery disease.
In case of any further doubts about the use of this medicine, the patient should consult their doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, ACEBIS can cause side effects, although not everybody gets them.
The patient should stop taking the medicine and contact their doctor immediately if they experience any of the following side effects:

• severe dizziness or fainting due to low blood pressure (common - may affect up to 1 in 10 people),
• worsening of heart failure causing increased shortness of breath and/or fluid retention (common - may affect up to 1 in 10 people),
• swelling of the face, lips, mouth, tongue, or throat, difficulty breathing (angioedema) (uncommon - may affect up to 1 in 100 people),
• sudden wheezing, chest pain, shortness of breath, or difficulty breathing (bronchospasm) (uncommon - may affect up to 1 in 100 people),
• abnormal or irregular heartbeats, chest pain (angina pectoris), or heart attack (uncommon - may affect up to 1 in 100 people),
• weakness or numbness of the arms or legs or problems with speech, which may be a sign of a possible stroke (frequency not known - cannot be estimated from the available data),
• pancreatitis, which may cause severe abdominal pain radiating to the back, accompanied by a very bad feeling (very rare - may affect up to 1 in 10,000 people),
• yellowing of the skin or eyes (jaundice), which may be a sign of liver inflammation (rare - may affect up to 1 in 1,000 people),
• skin rash, which often starts with red, itchy patches on the face, hands, or feet (erythema multiforme) (frequency not known - cannot be estimated from the available data).

ACEBIS is usually well tolerated, but like any medicine, it can cause side effects, especially at the beginning of treatment.

If the patient notices any of the following side effects, they should contact their doctor or pharmacist immediately:

Very common (may affect more than 1 in 10 people):

• slow heart rate.

Common (may affect up to 1 in 10 people):

• headache,
• dizziness,
• fainting, low blood pressure (hypotension), especially when standing up quickly or sitting up,
• numbness of the hands or feet,
• feeling cold in the hands or feet,
• cough,
• shortness of breath,
• sinusitis or bronchitis,
• chest pain,
• gastrointestinal disorders, such as nausea, vomiting, abdominal pain, difficulty swallowing, or indigestion, diarrhea, constipation,
• allergic reactions, such as skin rashes, itching,
• muscle cramps, muscle pain (myalgia),
• feeling weak,
• fatigue,
• blood tests showing high levels of potassium in the blood.

Uncommon (may affect up to 1 in 100 people):

• peripheral dizziness,
• taste disorders,
• tingling (paresthesia),
• vision disorders,
• tinnitus (feeling of ringing in the ears),
• stuffy nose, difficulty breathing, or worsening of asthma,
• nasal congestion,
• sudden flushing (especially of the face),
• mood swings,
• sleep disorders,
• depression,
• dry mouth,
• sweating,
• kidney problems,
• increased urination during the day than usual,
• impotence,
• high levels of eosinophils (a type of white blood cell),
• drowsiness,
• palpitations,
• rapid heart rate (tachycardia),
• irregular heart rate (atrioventricular conduction disorders),
• muscle weakness,
• arthralgia (joint pain),
• localized swelling (peripheral edema),
• fever,
• loss of appetite (anorexia),
• changes in laboratory parameters: increased levels of certain white blood cells (eosinophilia), increased levels of urea in the blood, increased levels of creatinine in the blood, increased activity of liver enzymes, increased levels of bilirubin in the serum,
• high levels of protein in the urine,
• mouth ulcers,
• breast enlargement in men.

Rare (may affect up to 1 in 1,000 people):

• nightmares, hallucinations,
• reduced tear secretion (dry eyes),
• redness, itching, swelling, or tearing of the eyes,
• hearing problems,
• liver inflammation, which may cause yellowing of the skin or eyes,
• vasculitis (inflammation of blood vessels),
• changes in laboratory parameters: increased levels of fat, decreased levels of red blood cells, white blood cells, or platelets, or hemoglobin levels.

Very rare (may affect up to 1 in 10,000 people):

• confusion,
• pancreatitis (which may cause severe abdominal pain radiating to the back),
• hair loss,
• appearance or worsening of a scaly skin rash (psoriasis), psoriasis-like rash,
• increased sensitivity of the skin to sunlight (photosensitivity reaction),

Frequency not known (cannot be estimated from the available data):

• discoloration, numbness, and pain in the fingers and toes (Raynaud's phenomenon),
• low levels of sodium, very low levels of sugar in the blood (hypoglycemia) in patients with diabetes,
• tongue inflammation.

During treatment with ACE inhibitors, side effects such as dark urine (concentrated urine), nausea, or vomiting, muscle cramps, confusion, and seizures may occur, which may be caused by abnormal secretion of antidiuretic hormone (ADH). If these symptoms occur, the patient should contact their doctor as soon as possible.

Reporting side effects

If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse.
Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Jerozolimskie Avenue 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder. By reporting side effects, it is possible to gather more information on the safety of the medicine.

5. How to store ACEBIS

The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the blister and carton after EXP.
The expiry date refers to the last day of the month.
Do not store above 30°C. Do not store in the refrigerator or freeze.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What ACEBIS contains

• The active substances of ACEBIS are ramipril and bisoprolol fumarate.
• The other excipients are: Contents of the capsule:lactose monohydrate, polyvinyl alcohol, sodium croscarmellose (E468), sodium stearyl fumarate, microcrystalline cellulose, calcium hydrogen phosphate anhydrous, crospovidone type A, colloidal anhydrous silica, magnesium stearate

AquaPolish P yellow coating: hypromellose (E464), hydroxypropylcellulose (E463), medium-chain triglycerides, talc (E553b), titanium dioxide (E171), yellow iron oxide (E172).
Capsule shell: titanium dioxide (E171), gelatin, red iron oxide (E172) - [in 10 mg+10 mg, 10 mg+5 mg, 5 mg+5 mg, 5 mg+2.5 mg capsules], yellow iron oxide (E172) - [in 10 mg+5 mg, 5 mg+5 mg, 5 mg+2.5 mg, 2.5 mg+2.5 mg, 2.5 mg+1.25 mg capsules], quinoline yellow (E104) - [in 5 mg+2.5 mg, 2.5 mg+2.5 mg, 2.5 mg+1.25 mg capsules].
Ink: shellac (E904), black iron oxide (E172), propylene glycol, concentrated ammonia solution, potassium hydroxide.

What ACEBIS looks like and contents of the pack

ACEBIS 2.5 mg + 1.25 mg, hard capsules
The capsule has a yellow cap with black printing "2.5 mg" and a white body with black printing "1.25 mg".
Contents of the 2.5 mg + 1.25 mg capsule: ramipril in the form of a white or almost white powder and bisoprolol fumarate in the form of one yellow, biconvex, film-coated, round tablet
ACEBIS 2.5 mg + 2.5 mg, hard capsules
The capsule has a yellow cap with black printing "2.5 mg" and a yellow body with black printing "2.5 mg".
Contents of the 2.5 mg + 2.5 mg capsule: ramipril in the form of a white or almost white powder and bisoprolol fumarate in the form of one yellow, biconvex, film-coated, round tablet
ACEBIS 5 mg + 2.5 mg, hard capsules
The capsule has an orange cap with black printing "5 mg" and a yellow body with black printing "2.5 mg".
Contents of the 5 mg + 2.5 mg capsule: ramipril in the form of a white or almost white powder and bisoprolol fumarate in the form of one yellow, biconvex, film-coated, round tablet
ACEBIS 5 mg + 5 mg, hard capsules
The capsule has an orange cap with black printing "5 mg" and an orange body with black printing "5 mg".
Contents of the 5 mg + 5 mg capsule: ramipril in the form of a white or almost white powder and bisoprolol fumarate in the form of one yellow, biconvex, film-coated, round tablet
ACEBIS 10 mg + 5 mg, hard capsules
The capsule has a reddish-brown cap with black printing "10 mg" and an orange body with black printing "5 mg".
Contents of the 10 mg + 5 mg capsule: ramipril in the form of a white or almost white powder and bisoprolol fumarate in the form of one yellow, biconvex, film-coated, round tablet
ACEBIS 10 mg + 10 mg, hard capsules
The capsule has a reddish-brown cap with black printing "10 mg" and a reddish-brown body with black printing "10 mg".
Contents of the 10 mg + 10 mg capsule: ramipril in the form of a white or almost white powder and bisoprolol fumarate in the form of two yellow, biconvex, film-coated, round tablets
BOPA/Aluminum/PVC/Aluminum blisters.
The blisters and patient information leaflet are packaged in a cardboard box.
Capsules are available in packs of:
10, 30, 60, or 100 capsules.
Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder

Manufacturer

Adamed Pharma S.A.
Marszałka Józefa Piłsudskiego 5
95-200 Pabianice
Date of last revision of the leaflet:May 2023